Low Follow-Up Rate for Colonoscopy After Abnormal Blood-Based Cancer Screening

A recent study published in the journal Gastroenterology reveals that less than half of patients who receive an abnormal result from a blood-based colorectal cancer screening undergo a follow-up colonoscopy within six months. This concern highlights a critical gap in the cancer detection process, potentially delaying diagnosis and treatment. The research analyzed data from over 6,000 individuals who used a commercial blood test for colorectal cancer (Shield by Guardant Health), finding that only 49% of those with abnormal results completed the necessary colonoscopy within the recommended timeframe. Notably, patients with Medicare Advantage plans were significantly less likely to receive timely follow-up, with only about a quarter doing so within six months. Factors such as fewer comorbidities increased the likelihood of follow-up, while age, race, and geographic region did not significantly influence the follow-up rate. Dr. Folasade May from UCLA emphasized that while blood-based screening tests are promising, their effectiveness relies heavily on Patient adherence to follow-up procedures. The study underscores the need for improved strategies to ensure patients complete the recommended diagnostic steps, which are vital for early detection and effective treatment of colorectal cancer. Ensuring higher follow-up rates could greatly enhance the impact of minimally invasive screening options and improve long-term patient outcomes.